Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | PDE4A | P27815 | 1/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.50 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.50 |
| ▸ | DPP4 | P27487 | 1/20 | 0.48 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19998591 | 1.00 | POLB (0.57) | POLBALDH1A1SMN1; SMN2MAPTUSP2 | |
| Methyl Alcohol SCHEMBL28445158 | 0.96 | POLB (0.54) | POLBALDH1A1SMN1; SMN2MAPTUSP2 | |
| SCHEMBL12235705 | 0.81 | RXFP1 (0.52) | POLBALDH1A1SMN1; SMN2MAPTMEN1 | |
| SCHEMBL16474469 | 0.81 | ALDH1A1 (0.54) | POLBALDH1A1SMN1; SMN2MAPTUSP2 | |
| SCHEMBL27048510 | 0.81 | MEN1 (0.51) | POLBALDH1A1MAPTDPP4MEN1 | |
| SCHEMBL16474467 | 0.81 | ALDH1A1 (0.54) | POLBALDH1A1SMN1; SMN2MAPTUSP2 | |
| SCHEMBL7909433 | 0.81 | ALDH1A1 (0.54) | POLBALDH1A1SMN1; SMN2MAPTUSP2 | |
| SCHEMBL22554286 | 0.81 | RXFP1 (0.52) | POLBALDH1A1SMN1; SMN2MAPTMEN1 | |
| SCHEMBL22554265 | 0.81 | RXFP1 (0.52) | POLBALDH1A1SMN1; SMN2MAPTMEN1 | |
| SCHEMBL20901728 | 0.79 | POLB (0.56) | POLBALDH1A1MEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111458447-B | Chinese wolfberry quality detection method based on spectral efficiency relationship | 贵州中医药大学 | 2023-03-31 | — | — | CN | disclosed |
| EP-3943490-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | Mission Therapeutics Limited (GB) | 2022-01-26 | — | — | EP | disclosed |
| EP-3842427-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | Mission Therapeutics Limited (GB) | 2021-06-30 | — | — | EP | disclosed |
| CN-106324989-B | Colored curable resin composition, color filter, and display device | 东友精细化工有限公司 | 2021-06-15 | — | — | CN | disclosed |
| CN-106324988-B | Colored curable resin composition, color filter, and display device | 东友精细化工有限公司 | 2021-06-04 | — | — | CN | disclosed |
| CN-111458447-A | Chinese wolfberry quality detection method based on spectral efficiency relationship | 贵州中医药大学 | 2020-07-28 | — | — | CN | disclosed |
| US-10343992-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | Missions Therapeutics Limited (GB) | 2019-07-09 | — | — | US | disclosed |
| US-20180086708-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2018-03-29 | — | — | US | disclosed |
| US-9206173-B2 | Heterocyclic compounds for the treatment of stress-related conditions | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-08 | — | — | US | disclosed |
| US-9206173-B2 | Heterocyclic compounds for the treatment of stress-related conditions | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-12-08 | — | — | US | disclosed |
| US-20120065189-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-03-15 | — | — | US | disclosed |
| US-20120065189-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-03-15 | — | — | US | disclosed |
| US-8034949-B2 | Pyrrolidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-10-11 | — | — | US | disclosed |
| US-8034949-B2 | Pyrrolidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-10-11 | — | — | US | disclosed |
| WO-2010137738-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-12-02 | — | — | WO | disclosed |
| US-20070167440-A1 | Novel pyrrolidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-07-19 | — | — | US | disclosed |
| US-20070167440-A1 | Novel pyrrolidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-07-19 | — | — | US | disclosed |
| CN-1374349-A | Process for producing asymmetric hypomethyl dye | BAYER AG (DE) | 2002-10-16 | — | — | CN | disclosed |
| US-6465659-B2 | REACTING 3,3-TRIMETHYL-2-METHYLENEINDOLINE DERIVATIVE DISSOLVED IN A SOLVENT WITH 5-HYDROXY-1-SUBSTITUTED OR UNSUBSTITUTED PHENYL PYRAZOLE DERIVATIVE AND TRIALKYL ORTHOFORMATE TO FORM ASYMMETRICAL METHINE DYES | BAYER AKTIENGESELLSCHAFT (DE) | 2002-10-15 | — | — | US | disclosed |
| US-20020128489-A1 | PROCESS FOR PREPARING ASYMMETRICAL METHINE DYES | LANXESS DEUTSCHLAND GMBH (DE) | 2002-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167440-A1 | Novel pyrrolidine compound and a process for preparing the same | CNR1, CNR2, OPRD1 | POLB 3015/4885ALDH1A1 2888/4885SMN1; SMN2 4282/4885 |
| US-10343992-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP20, USP10 | POLB 809/4885ALDH1A1 1264/4885SMN1; SMN2 3078/4885 |
| US-20180086708-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | USP30, USP20, USP10 | POLB 809/4885ALDH1A1 1264/4885SMN1; SMN2 3078/4885 |
| US-20020128489-A1 | PROCESS FOR PREPARING ASYMMETRICAL METHINE DYES | NISCH, CMPK1, CYP3A4 | POLB 2065/4885ALDH1A1 541/4885SMN1; SMN2 2390/4885 |
| US-20120065189-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS | NR3C1, NR3C2, CRH | POLB 4094/4885ALDH1A1 461/4885SMN1; SMN2 3455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.